Ruth Keri

17PUBLICATIONS
70CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer geneticsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Oct 01, 2026
The small molecule inhibitor SU056-mediated targeting of YB1 inhibits the Rb pathway in triple negative breast cancer tumors.

|Aug 20, 2026
Novel transplantable mouse cell line model recapitulates invasive lobular breast carcinoma (ILC) phenotype and immune microenvironment.

|May 25, 2026
Integrated Collagen Architecture and Composition Improve Risk Stratification in Triple-Negative Breast Cancer.

|Sep 11, 2025
Targeting the ERα DBD-LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation.

Han Wang, Yuxuan Luo, Sandeep Artham

|Jan 23, 2025
Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors.

Leslie Cuellar-Vite, Elyse M Donaubauer, Kristen L Weber-Bonk

|Jul 22, 2024
Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer.

Katrina M Piemonte, Natasha N Ingles, Kristen L Weber-Bonk

Pageof 3

Frequent Collaborators

5 joint publications

Kristen Weber Bonk

4 joint publications

Darcie Seachrist

3 joint publications

Salendra Singh

3 joint publications

Leslie Cuellar-Vite